Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.39 |
| ▸ | LPL | P06858 | 3/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16427002 | 0.88 | KDM4E (0.49) | BRD4PDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL31430344 | 0.85 | LPL (0.36) | BRD4PDE3BPDE3APRMT5WDR77 | |
| SCHEMBL13058013 | 0.78 | LIPG (0.46) | PRMT5WDR77LPLLIPG | |
| SCHEMBL31116974 | 0.76 | PGR (0.47) | PDE3BPDE3ALPLLIPG | |
| SCHEMBL421621 | 0.75 | CYP11B1 (0.47) | PDE3BPDE3AALDH1A1SMN1; SMN2 | |
| SCHEMBL30284843 | 0.75 | CYP11B1 (0.47) | PDE3BPDE3AALDH1A1SMN1; SMN2 | |
| SCHEMBL2722518 | 0.74 | BRD4 (0.60) | BRD4PDE3BPDE3AKDM4EALDH1A1 | |
| SCHEMBL30905971 | 0.73 | LPL (0.41) | PRMT5WDR77LPLLIPG | |
| SCHEMBL429171 | 0.73 | PGR (0.52) | — | |
| SCHEMBL19411818 | 0.73 | LIPG (0.38) | PRMT5WDR77LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| US-11780830-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-10-10 | — | — | US | disclosed |
| US-20210317110-A1 | TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2021-10-14 | — | — | US | disclosed |
| US-10995086-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2021-05-04 | — | — | US | disclosed |
| US-20190322655-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322655-A1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SLC10A1, VAPB, VAT1 | BRD4 2341/4885PDE3B 2224/4885PDE3A 1754/4885 |
| US-20210317110-A1 | TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SLC10A1, VAT1, LIPC | BRD4 2660/4885PDE3B 2665/4885PDE3A 2090/4885 |
| US-11780830-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | SLC10A1, VAT1, LIPC | BRD4 2660/4885PDE3B 2665/4885PDE3A 2090/4885 |
| US-10995086-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | SLC10A1, VAT1, VAPB | BRD4 2757/4885PDE3B 2625/4885PDE3A 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.